Heitzer, Thomas <br/><br/>
Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.  [electronic resource] 

 -  Circulation  Aug 2003 
 - 536-41 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4539 
<br/><br/><label>Standard No.: </label>10.1161/01.CIR.0000081774.31064.62  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetylcholine--pharmacology<br/>Biological Availability<br/>Blood Flow Velocity--drug effects<br/>Blood Platelets--drug effects<br/>Coronary Artery Disease--drug therapy<br/>Endothelium, Vascular--drug effects<br/>Enzyme Inhibitors--pharmacology<br/>Eptifibatide<br/>Forearm--blood supply<br/>Humans<br/>Male<br/>Middle Aged<br/>Nitric Oxide--metabolism<br/>Nitric Oxide Donors--pharmacology<br/>Peptides--pharmacology<br/>Platelet Aggregation Inhibitors--pharmacology<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Plethysmography<br/>Tirofiban<br/>Tyrosine--analogs & derivatives<br/>Vasodilation--drug effects<br/>Vasodilator Agents--pharmacology<br/>Vasomotor System--drug effects<br/>omega-N-Methylarginine--pharmacology